Weekly Rundown: Key Catalysts for Small-Cap Stocks (September 29–October 3)

From recent disclosures to corporate shifts, we’ve highlighted the top small-cap catalysts to watch. Here’s your weekly preview (September 29–October 3).

--

Companies Participating in the Lytham Partners Fall 2025 Investor Conference: Taking place virtually on Tuesday, September 30, 2025

JAGX · DRTS · LOCE · SND · PYPD · NRXS · RVPH · IPM · SNES · AYTU · BFRI · SNOA · KGEI · BFRI


Other Companies with Catalysts This Week:

● FFAI / QLGN – On Sept 19, 2025, Qualigen entered a $41M private placement with investors, led by Faraday Future (FFAI). The deal includes common stock ($2.246/share) and Series B preferred ($1,000/share). Proceeds will fund debt repayment, operations, and a new cryptocurrency treasury initiative. Closing of the Offering is expected on or about Sept 29, 2025, subject to customary conditions.

● MDCX – Members of the executive team will participate in a live fireside chat on Monday, September 29, 2025, hosted by Kumaraguru Raja, Ph.D., Senior Biotechnology Analyst at Brookline Capital Markets.

● LRE – On September 5, 2025, the Board of Directors approved a dividend distribution of 10 JPY (about $0.07) per ADR, totaling approximately $923,810 (139,419,000 JPY). The dividend is subject to shareholder approval on September 29, 2025, with distribution set for September 30, 2025. The company’s last dividend was $0.02 per share on September 30, 2024.

● ARAY – The company will host an investor and analyst discussion on Monday, September 29, 2025, during the ASTRO Annual Meeting in San Francisco and online. Presentations begin at 1:30 pm PT and will cover adaptive radiotherapy, integration into clinical practice, and imaging leadership perspectives.

● CLYM – Climb Bio will host the CLYM116 webcast event on Monday, September 29, 2025, at 8:00 a.m. ET, joined by nephrologist Dr. Craig E. Gordon. The event will highlight CLYM116, a monoclonal antibody targeting APRIL for IgA nephropathy, featuring a unique "sweeper" mechanism intended to improve efficacy and dosing convenience.

● HTCR – HeartCore announced the launch of HeartCore CMS Version 13 on September 30, 2025. The update introduces a redesigned, user-friendly interface and AI-powered SEO, GEO tools, and recommendation engines to improve content management and digital marketing performance.

● ELDN – Steve Perrin, Ph.D., President and CSO, will participate in a plenary session at the 18th Congress of the International Xenotransplantation Association in Geneva, Switzerland, from September 30–October 3, 2025.

● EONR – The company will host a special conference call on Tuesday, September 30, 2025, at 2:30 p.m. ET to discuss $45.5 million in funding and a farmout agreement.

● PHIO – CEO Robert Bitterman will present updates on INTASYL siRNA technology and the PH-762 trial for skin cancers on Tuesday, September 30, 2025, at 12:00 p.m. ET during the Virtual Non-Deal Roadshow Series. Interim Phase 1b results recently showed positive safety and efficacy.

● ALT – The company will participate in the Stifel 2025 Virtual Cardiometabolic Forum on Tuesday, September 30, 2025, with a fireside chat at 10:30 a.m. ET.

● ADVM – Adverum announced that it expects to complete screening in its pivotal Phase 3 ARTEMIS trial evaluating Ixo-vec in wet AMD by September 30, 2025. Full enrollment of at least 284 patients is now expected in 4Q 2025.

● NVNI – CEO Pierre Schurmann will deliver the keynote, “LatAm Giants Mastering Expansion: The Global Playbook,” at Brazil Investment Week in London on September 30, 2025.

● IINN – The company will debut its HYLA blood sensor at the U.S. ELSO Annual Conference in Washington, D.C., running September 27–30, 2025.

● TSI – Announced a quarterly distribution of $0.065 per share, payable October 10, 2025, to shareholders of record on September 30, 2025.

● AGL – Management will participate in a fireside chat at the 2025 Jefferies Healthcare Services Conference on Tuesday, September 30, 2025, at 8:45 a.m. ET.

● LFT – Declared a Q3 2025 dividend of $0.04 per share, payable October 15, 2025, to shareholders of record on September 30, 2025.

● RC – Declared a Q3 2025 cash dividend of $0.125 per share, payable October 31, 2025, to shareholders of record on September 30, 2025.

● CHMI – Declared a Q3 2025 dividend of $0.10 per share, payable October 31, 2025, to shareholders of record on September 30, 2025.

● ATYR – Will present EFZO-FIT™ topline results at the European Respiratory Society Congress on Tuesday, September 30, 2025, at 8:44 a.m. CEST in Amsterdam.

● AFCG – Declared a quarterly dividend of $0.15 per share, payable October 15, 2025, to shareholders of record on September 30, 2025.

● IPHA – CFO Frédéric Lombard will participate in the European Midcap Event in Paris from September 30 to October 1, 2025.

● WGRX – Hosting the Skyline Signature Series Webinar virtually on Tuesday, September 30, 2025, at 12:00 p.m. ET.

● CLRB – Will present data on its actinium-based radio-conjugate at the AACR Special Conference on Pancreatic Cancer Research on September 30, 2025, from 6:00–9:00 p.m. ET.

● ARBE – Will join the Evercore ADAS, AV & AI Forum in New York City on Tuesday, September 30, 2025, featuring in-person meetings and a fireside chat.

● ACRE – Declared a Q3 2025 dividend of $0.15 per share, payable October 15, 2025, to shareholders of record on September 30, 2025.

● BGS – Declared a quarterly dividend of $0.19 per share, payable October 27, 2025, to shareholders of record on September 30, 2025.

● BHR – Declared a Q3 2025 dividend of $0.05 per share, payable October 15, 2025, to shareholders of record on September 30, 2025.

● BZAI – Will participate in a panel at the Milken Institute 2025 Asia Summit in Singapore from October 1–3, 2025.

● GPMT – Declared a Q3 2025 dividend of $0.05 per share, payable October 15, 2025, to shareholders of record on October 1, 2025.

● CADL – Will present Phase 3 data from CAN-2409 in prostate cancer at the ASTRO Annual Meeting, September 27–October 1, 2025, in San Francisco.

● ALLR – CEO Thomas Jensen will present at the Biomarkers & Precision Medicine 2025 Conference in London on October 1, 2025, at 4:00 p.m. His interview with Oxford Global will also be featured on their content portal.

● SBC – Announced the October 1, 2025 launch of Hada no Aozora Clinic in Tokyo, a hybrid dermatology clinic offering insurance-covered care and private-pay aesthetic treatments.

● CNTB – Will deliver two poster presentations at the European Respiratory Society Congress, September 27–October 1, 2025, in Amsterdam and virtually.

● FUFU – Will participate in TOKEN2049 Singapore, October 1–2, 2025.

● CHRS – Will join the UBS Virtual Oncology Day on Wednesday, October 1, 2025, at 1:00 p.m. ET.

● SVRA – Accepted three abstracts for poster presentation at the ERS Congress (Sept 27–Oct 1, 2025, Amsterdam). The company will also host a symposium on advances in autoimmune pulmonary alveolar proteinosis.

● LWLG – Executives will attend the European Conference on Optical Communication (ECOC) in Copenhagen, Sept 28–Oct 2, 2025.

● GNS – Hosting the Genius Future Summit in Asia on October 2–3, 2025, positioned as the region’s top event for entrepreneurs and changemakers.

● QNCX – Will host a virtual Investor Day on Thursday, October 2, 2025, from 10:00 a.m. to 12:00 p.m. ET, featuring leadership presentations on clinical and corporate updates.

● NFGC – VP Fiona Childe will present at the Munich Mining Conference on October 3, 2025, at 11:55 a.m. CEST, and meet with investors October 3–4, 2025.

● EVAX – Participating in Vax On Vaccines: Present and Future in Oncology on October 1, 2025, in Milan.

● GPUS – Gresham Worldwide, majority-owned by GPUS, has received final court approval of its Chapter 11 plan of reorganization, clearing the way to emerge from bankruptcy on October 1, 2025.

● BMRA – Received a new Proprietary Laboratory Analysis CPT code for its inFoods® IBS test. The code will take effect October 1, 2025, allowing reimbursement claims with Medicare and private insurers.

● SDOT – Signed a letter of intent on September 3, 2025, to sell its Pokemoto and Muscle Maker Grill chains for $4.25 million. Closing is expected between October 3–18, 2025, pending approvals.

● SPRC – AutoMax Motors filed a motion with the Jerusalem District Court regarding its merger with SciSparc Ltd. The court granted a stay until September 30, 2025, or until closing conditions are clarified.

● HTOO – Executed a Heads of Terms with Alien Energy for a specialized fuel project in South Africa. Closing is targeted for October 1, 2025, pending definitive agreements.

● SBLX – StableX announced its first purchase of FLUID tokens and noted that FLUID will begin buybacks starting October 1, 2025, using all revenue to support token price growth.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.